dihexa comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Analytical confirmation generally combines a separation method with a detection method. Reverse-phase high-performance liquid chromatography can assess purity, while mass spectrometry supports molecular identity. For research-grade material, a certificate of analysis may report a batch-specific purity value, but it does not guarantee biological activity or safety. Regulatory frameworks vary by country; many jurisdictions treat dihexa as a research chemical not intended for human consumption. Purchasers should verify local rules and supplier documentation. The absence of official standards makes independent testing and careful record-keeping important for laboratory work.
Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.
Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.
Chemically, dihexa is a short peptide-like molecule with nonstandard components. Its structure includes tyrosine and isoleucine residues linked to a hexanoic acid group and an aminohexanoic amide segment. This design distinguishes it from endogenous angiotensin IV, though the two are discussed together because of shared origins. Published summaries classify it as a small synthetic peptide with lipophilic features that may influence how it crosses biological barriers in experimental systems. Exact conformational details depend on the specific salt or free base form.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Typical for lyophilized peptide-like research chemicals. |
| Solubility | Limited in water; soluble in some organic solvents | DMSO is commonly used for stock solutions. |
| Typical storage | -20 °C or below, desiccated, protected from light | Avoid repeated freeze-thaw cycles. |
| Purity assessment | Reverse-phase HPLC with UV detection | Mass spectrometry is often used for identity confirmation. |
| Common document | Certificate of analysis | Batch-specific; does not establish safety or efficacy. |
Dihexa is commonly handled as a lyophilized powder in laboratory settings. Storage at -20 °C in a desiccated, light-protected container is typical for peptides. Repeated freeze-thaw cycles can degrade the material, so aliquoting is often recommended. Aqueous solutions may be less stable than organic stocks and should be prepared fresh when possible. Personnel should follow institutional safety procedures and avoid uncontrolled exposure. Because human effects are not well characterized, handling precautions are prudent.
The proposed mechanism of dihexa centers on activation of the hepatocyte growth factor receptor, also called c-Met. Some studies suggest it acts as a mimetic of hepatocyte growth factor, promoting signaling pathways involved in synapse formation. Other work has explored interactions with angiotensin IV pathways, but the exact binding targets remain uncertain. Laboratory findings come mainly from cell cultures and animal models. Whether these mechanisms operate similarly in humans is an open question. Researchers have not established a single, universally accepted mechanism of action.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
===== Translation/antisense ===== Genomics has not only helped find targets for many antivirals, it has provided the basis for an entirely new type of drug, based on "antisense" molecules. These are segments of DNA or RNA that are designed as complementary molecules to critical sections of viral genomes, and the binding of these antisense segments to these target sections blocks the operation of those genomes. A phosphorothioate antisense drug named fomivirsen has been introduced, used to treat opportunistic eye infections in AIDS patients caused by cytomegalovirus, and other antisense antivirals are in development. An antisense structural type that has proven especially valuable in research is morpholino antisense. Morpholino oligos have been used to experimentally suppress many viral types:
Sir Joseph John Thomson (18 December 1856 – 30 August 1940) was a British physicist. He received the 1906 Nobel Prize in Physics "in recognition of the great merits of his theoretical and experimental investigations on the conduction of electricity by gases." In 1897, he showed that cathode rays were composed of previously unknown negatively charged particles (now called electrons), which he calculated must have bodies much smaller than atoms and a very large charge-to-mass ratio. The electron was the first subatomic particle to be discovered. Thomson is credited with finding the first evidence for isotopes of a stable (non-radioactive) element in 1912, as part of his exploration into the composition of canal rays (positive ions). His experiments to determine the nature of positively charged particles, with Francis William Aston, were the first use of mass spectrometry and led to the development of the mass spectrograph. Thomson was an influential teacher, and seven of his students went on to win Nobel Prizes: Ernest Rutherford (Chemistry 1908), Lawrence Bragg (Physics 1915), Charles Barkla (Physics 1917), Francis Aston (Chemistry 1922), Charles Thomson Rees Wilson (Physics 1927), Owen Richardson (Physics 1928) and Edward Appleton (Physics 1947). His son, George Paget Thomson, shared the 1937 Nobel Prize in Physics with Clinton Davisson "for their experimental discovery of the diffraction of electrons by crystals".
The TAAR1 full agonist RO5166017 and the high-efficacy TAAR1 partial agonist RO5256390, as well as the antipsychotic olanzapine, produced similar effects in these paradigms. Relatedly, RO5263397 produced a pattern of brain activity in rodents similar to that of antipsychotics. In addition, RO5263397 potently suppresses hyperlocomotion in dopamine transporter (DAT) knockout mice. The preceding findings suggest that TAAR1 agonists like RO5263397 have antipsychotic-like properties. In contrast to classical antipsychotics however, RO5263397 did not show extrapyramidal-like symptoms like catalepsy in mice, and instead partially prevented haloperidol-induced catalepsy, suggesting the potential for an improved tolerability profile. RO5263397 has been shown to reduce behavioral sensitization induced by cocaine in mice. Similarly, it reduces the expression but not development of conditioned place preference (CPP) by cocaine in mice. Analogously to cocaine, RO5263397 dose-dependently attenuates behavioral sensitization to methamphetamine, reduces self-administration of methamphetamine, and blocks reinstatement of methamphetamine-seeking behaviors in rodents. It also attenuates methamphetamine-induced impulsivity in rodents. In general, the drug has been found to suppress methamphetamine-, cocaine, and nicotine-induced stimulant-like and reinforcing effects in animals in vivo. Analogous findings have been made for morphine and ethanol. RO5263397 has similar effects compared to TAAR1 full agonists like RO5256390 in vivo in terms of psychostimulant modulation.
=== seg-seo === seganserin (INN) seglitide (INN) Sehippy seladelpar (INN) selamectin Selarsdi Selax Seldane Selecor Select 1/35 Selectol selegiline (INN) selenomethionine (75 Se) (INN) Selepen selepressin (INN) Selestoject seletracetam (USAN, (INN)) selexipag (INN) selfotel (INN) seliciclib (INN) selodenoson (USAN) Selpak selprazine (INN) Selsun Selsun Blue seltraposin (INN) selumetinib (USAN) selurampanel (INN) selvacovatein (INN) semagacestat (USAN, INN) semaglutide (INN) sematilide (INN) semduramicin (INN) Semicid Semilente semorphone (INN) semotiadil (INN) semparatide (INN) Semprex-D semuloparin (USAN, INN) semustine (INN) Senexon senicapoc (USAN) Sennatural senofilcon A (USAN) Senokot Senolax Sensipar Sensorcaine Senvelgo seocalcitol (INN)
=== Dual-mode === In dual-mode, the mobile and stationary phases are reversed part way through the separation experiment. This requires changing the phase being pumped through the column as well as the direction of flow. Dual-mode operation is likely to elute the entire sample from the column but the order of elution is disrupted by switching the phase and direction of flow.
Sources: en.wikipedia.org
== Toxicity == A study was performed to assess the toxicity effects of doxorubicin-loaded polymeric nanoparticle systems. It was found that doses up to 400 mg/kg of PBCA nanoparticles alone did not cause any toxic effects on the organism. These low toxicity effects can most likely be attributed to the controlled release and modified biodistribution of the drug due to the traits of the nanoparticle delivery system. Toxicity is a highly important factor and limit of drug delivery studies, and a major area of interest in research on nanoparticle delivery to the brain.
ABRF 2025, 23–28 March 2025, Las Vegas, NV ABRF 2024, 21–24 April 2024, Minneapolis, MN ABRF 2023, 7–10 May 2023, Boston, MA ABRF 2022, 27–30 March 2022, Palm Springs, CA ABRF 2021, 7–11 March 2021, virtual meeting due to COVID-19 ABRF 2020, 29 February – 3 March 2020, Palm Springs, CA ABRF 2019, 23–26 March, San Antonio, Texas; 30 Years of Challenging the Limits of Science and Technology, Opening Doors for the Future ABRF 2018, 22–25 April, Myrtle Beach, South Carolina; The Premier Conference for Core Services ABRF 2017, 25–28 March, San Diego, California; A Forum for Advancing Today's Core Technologies to Enable Tomorrow's Innovations ABRF 2016, 20–23 February, Ft. Lauderdale, Florida; Innovative Technologies Accelerating Discovery ABRF 2015, 28–31 March, St.
==== United Arab Emirates ==== The UAE takes an exceptionally strict line on medicines, with many common drugs, notably anything containing codeine being banned unless one has a notarized and authenticated doctor's prescription. Visitors breaking the rules, even inadvertently, have been deported or imprisoned. The US Embassy to the UAE maintains an unofficial list of what may not be imported.
== Anaphylaxis during general anaesthesia == Administration of pholcodine causes production of antibodies linked with fatalities during surgery, when essential neuromuscular blocking agents (NMBAs) are administered to prevent patient movement under general anaesthesia. These antibody levels gradually fall to low levels several years after last dose of pholcodine. However, the presence of these antibodies causes a 300-fold increase in risk of anaphylaxis during anaesthesia. The link was suspected when neighbouring Norway and Sweden were found to have tenfold differences of surgical anaphylaxis deaths. Sweden had no products approved containing pholcodine, whereas 40% of the population in Norway had consumed the single approved pholcodine product. Norway withdrew pholcodine from the market in 2007, and the prevalence of anti-suxamethonium antibodies fell by over 80% in two years. A corresponding fall in anaesthesia deaths followed. A similar disparity exists between NMBA anaphylaxis rates in Australia, where pholcodine consumption is high and the US, where pholcodine is banned. In the US, anaphylaxis rates are so low that some anaesthetists question the existence of such reactions to NMBAs. Conversely, Australian anaesthetists have requested a ban on pholcodine due to the high anaphylaxis rate in the country. However, the Therapeutic Goods Administration declined the request in January 2015, pending further reviews to follow. In February 2023, the Therapeutic Goods Administration reversed its previous decision and banned products containing pholcodine.
This leads to a condition called anorexia cachexia syndrome (ACS) and additional nutrition or supplementation is unlikely to help. Symptoms of weight loss from ACS include severe weight loss from muscle rather than body fat, loss of appetite and feeling full after eating small amounts, nausea, anemia, weakness and fatigue. Serious weight loss may reduce quality of life, impair treatment effectiveness or recovery, worsen disease processes and be a risk factor for high mortality rates. Malnutrition can affect every function of the human body, from the cells to the most complex body functions, including:
Sources: en.wikipedia.org
=== Runoff and percolation === Solid bait and liquid insecticides, especially if improperly applied in a location, get moved by water flow. Often, this happens through nonpoint sources where runoff carries insecticides in to larger bodies of water. As snow melts and rainfall moves over and through the ground, the water picks applied insecticides and deposits them in to larger bodies of water, rivers, wetlands, underground sources of previously potable water, and percolates in to watersheds. This runoff and percolation of insecticides can effect the quality of water sources, harming the natural ecology and thus, indirectly effect human populations through biomagnification and bioaccumulation.
The Northern Ireland Executive is restored after the DUP ends its two-year boycott; Sinn Féin's Michelle O'Neill is appointed First Minister, becoming the first nationalist politician to hold the post, while the DUP's Emma Little-Pengelly is appointed deputy. A third round of joint UK–US air strikes are launched against Houthi rebels, targeting three sites in Yemen. Defence Secretary Grant Shapps says the latest strikes are "not an escalation" of the conflict. Esther Martin, a 68-year-old woman, is killed by dogs while visiting her grandson for the weekend in Jaywick, near Clacton-on-Sea, Essex. 4 February – CCTV footage of alkali attack suspect Abdul Shakoor Ezedi in a Tesco store is shown by the police, as a reward of £20,000 is offered for information leading to his capture. 5 February Buckingham Palace announces that King Charles III has been diagnosed with cancer and will postpone public duties while undergoing treatment. The Met Office issues a yellow weather warning for snow for large parts of north Wales, and northern and central England, for 8 February as unseasonably mild temperatures are replaced by colder weather. A 16-year-old boy is found guilty of plotting to launch a terrorist attack at the Isle of Wight Festival following a trial at Kingston Crown Court. The UK government launches a six-week consultation on plans for Martyn's Law, which would make provisions to better protect the public against potential acts of terrorism.
== External links == JPL Develops High-Speed Test to Improve Pathogen Decontamination at the Wayback Machine (archived 2016-03-04) at JPL. Spotting Spores at the Wayback Machine (archived 2016-03-04) at Astrobiology Magazine.
=== Legal status === On 24 March 2022, the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Camcevi, intended for the treatment of the cancer of the prostate in adult men when the cancer is "hormone-dependent", which means that it responds to treatments that reduce the levels of the hormone testosterone. The applicant for this medicinal product is Accord Healthcare S.L.U. Leuprorelin was approved for medical use in the European Union in May 2022.
intercalating agent Any chemical compound (e.g. ethidium bromide) that disrupts the alignment and pairing of bases in the complementary strands of a DNA molecule by inserting itself between the bases.
Sources: en.wikipedia.org
Dry powder is usually kept frozen, desiccated, and protected from light. Solutions are often aliquoted to avoid repeated freeze-thaw cycles. Specific stability data for dihexa are limited, so general peptide storage practices are commonly used.
Reverse-phase HPLC is commonly used to estimate purity, and mass spectrometry helps confirm molecular identity. Certificates of analysis may summarize these results. Independent testing can provide additional verification when standards are unavailable.
In many countries, dihexa is not approved as a medicine and is sold only for research purposes. Regulations differ by jurisdiction, and import or possession rules may apply. Buyers should confirm local legal status before obtaining it.
It is a synthetic peptide analog of angiotensin IV studied mainly in laboratory and animal research. It is not an approved medicine. Human clinical data are limited.